secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001770787-25-000003
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics reports preliminary Q4 2024 revenue of $165M, down 10% YoY but up 9% sequentially
--------------------------------------------------------------------------------

- FY2024 revenue ~$610.8M (-1% YoY); Q4 revenue ~$165M (-10% YoY, +9% sequentially).
- Instruments Q4 revenue $24.4M (-37% YoY); consumables $133.5M (-5% YoY); services $7.1M (+35% YoY).
- Cumulative instruments deployed >7,000; cash and equivalents ~$393M.
- Preliminary and unaudited; subject to adjustment after year-end close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078725000003/0001770787-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078725000003/txg-20250112.htm
  HTML page:      https://secwatch.observer/filing/0001770787-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer